BioActors’ citrus extract supplement could transform management of metabolic syndromes, experts reveal
02 Oct 2023 --- Recent clinical and pre-clinical studies suggest that MicrobiomeX – a blend of Citrus sinensis (sweet orange) and Citrus paradisi (grapefruit) extracts – could support gut microbiota in individuals with metabolic syndrome.
In recent years, the field of nutritional supplements has witnessed a dynamic shift in consumer needs and preferences. People are becoming increasingly conscious of their health and well-being, prompting the industry to continuously develop new solutions.
Developed by BioActor, MicrobiomeX is a clinically validated blend of extracts that are naturally rich in flavonoids, which are known for their anti-inflammatory and antiviral properties.
Managing metabolic syndrome
The researchers highlight that the significance of a healthy gut microbiome cannot be overstated. Research has shown that our gut microbiota plays a crucial role in various aspects of our health, from digestion to immunity and even mental well-being.
However, they note that the modern Western diet and lifestyle have been linked to the development of metabolic disorders and an imbalance in the gut microbiota. This underscores the importance of interventions aimed at maintaining a healthy gut.
A recent peer-reviewed study published in the journal Foods sheds light on the potential of MicrobiomeX to positively influence the intestinal microbiome, particularly in individuals displaying traits of metabolic syndrome.
Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and Type 2 diabetes. It includes factors like obesity, high blood pressure and elevated blood sugar levels.
Boosting with butyrate
Conducted by scientists from Maastricht University’s department of gastro-enterology and in partnership with BioActor, the study included 50 adult subjects with features of metabolic syndrome.
The participants were divided into two groups, one receiving 500 mg of the supplement daily for 12 weeks and the other receiving a placebo.
According to the researchers, after the 12-week supplementation period, the MicrobiomeX group exhibited a significant shift in their short-chain fatty acid (SCFA) profile, particularly toward an increase in butyrate.
Butyrate is a type of SCFA known for its health-promoting properties in the gut. Additionally, an increase in SCFA production was observed in an in vitro model, further reinforcing the potential of MicrobiomeX to modulate gut health.
Furthermore, the study found a trend toward a reduction in calprotectin levels in the MicrobiomeX group. Calprotectin is a marker of gut inflammation and its reduction suggests a potential decrease in gut inflammation, a key factor in various digestive disorders.
These findings underscore the potential of MicrobiomeX as a valuable tool in supporting gut health and, consequently, overall well-being.
Mastering the microbiome
BioActor further states that as consumers become increasingly health-conscious and seek science-backed solutions, MicrobiomeX offers an alternative to common prebiotics and serves as an ideal partner for synbiotic formulations aimed at enhancing gut health and immunity.
Additionally, the company states that the dynamic landscape of nutritional supplements demands constant innovation and that MicrobiomeX is a promising and scientifically validated addition to the industry.
Moreover, its ability to positively influence the gut microbiome, reduce gut inflammation and increase SCFA production highlights its potential as a valuable asset in the quest for better digestive health and overall wellness.
William Bradford Nichols
